328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09

Sara M. Tolaney, Romualdo Barroso‐Sousa, Z. Jiang, Y.H. Park, Mothaffar F. Rimawi, C. Saura Manich, Andreas Schneeweiß, Masakazu Toi, Tinghui Yu, Jagdish Shetty, Pia Herbolsheimer, Sibylle Loibl